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Abstract 
Background: There is no global consensus for the optimal management of HCC. Most of patients at the time of diag-
nosis are not candidate for potentially curative therapy. The study aimed to evaluate the efficacy of low dose capecit-
abine combined with sorafenib in subset of Egyptian HCV patients presented with advanced HCC unfit for surgical or 
locoregional therapies.
Methods: 15 patients with advanced HCC, unfit for surgical or locoregional intervention, with PS <2 recieved 
Capecitabine 500 mg/day with sorafeneb 200 mg twice daily till normalization of AFP then the treatment was modi-
fied to capecitabine 250 mg every other day and sorafenib 400 mg once daily. They were followed every 3 months for 
size, number of focal masses and AFP. 30 patients were selected as a control group, they received supportive therapy 
(n = 15) or sorafenib only (n = 15).
Results: After 10 months of therapy, 6 patients showed complete response (40 %) with complete recanalization of 
portal vein (n = 2) and treatment was stopped and the others (n = 4) showed partial portal vein recanalization so, 
treatment is continued till now. 1 patient (6.7 %) showed recurrence of the disease and died after 1 month, 8 patients 
showed partial response (53.3 %) and still on treatment. The control groups showed a highly significant reduction in 
survival when compared to patients who received capecitabine and sorafenib (12.9 ± 2.1, 7.9 ± 0.9, 4.5 ± 1.3 months, 
p = 0.000).
Conclusions: Combined low dose capecitabine and sorafenib proved to be safe with low toxicity profile and 
deserves further attention as a convenient, outpatient-based chemotherapy in patients with advanced HCC.
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Background
The continued appearance of new cases of hepatocellu-
lar carcinoma (HCC) with horribly increasing incidence 
making it the fifth common worldwide solid tumor, 
unfortunately, most of the cases present in an advanced 
or inoperable stage (Parkin et al. 1999).
In Egypt, the majority of patients are due to HCV, and 
actually, they present lately with reduced median survival 
and so therapy in most cases is palliative. The treatment 
options either curative in the form of hepatic resection 
or liver transplantation and palliative to include tran-
scatheter arterial chemoembolization (TACE) which is 
associated with a partial response in 10–55 %, radioem-
bolization, and medical therapy with sorafenib which is 
an oral multikinase inhibitor that had led to significant 
lengthening of short term-survival when compared to 
placebo (Lovet et al. 2008).
Alfa-fetoprotein (AFP) is a useful marker in patients 
with cirrhosis and focal hepatic masses. Values exceeding 
400  ng/ml are highly suggestive of HCC. A persistently 
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elevated AFP above normal value without abnormal radi-
ological findings may predict the future development of 
HCC (Forner et  al. 2009). About 50–70  % of advanced 
HCC secrete AFP (Peng et al. 2004).
There are no established guidelines for the adequate 
management of HCC, however according to Barcelona 
Clinic Liver Cancer (BCLC) staging system which is a 
widely endorsed system; patients with early HCC defined 
as a single nodule or three nodules  <3  cm in diameter 
and a performance status (PS) score of 0 with the absence 
of extrahepatic seedling, are suitable for potentially cura-
tive therapies as surgical resection, orthotopic liver trans-
plantation or interventional ablation by radiofrequency, 
microwave or ethanol injection.
Patients with adequate liver function and still asymp-
tomatic (PS = 0) with large (>5 cm) or multifocal tumors 
without vascular or extrahepatic invasion can be treated 
with transarterial chemoembolization (TACE) (Lopez 
et al. 2006). Careful analysis of all randomized controlled 
trials showed that treatment with TACE is associated 
with a significantly higher 2-year survival rate than in 
untreated groups (Llovet et al. 2003).
Better results were achieved with the use of gela-
tin sponge particles and an emulsion of cisplatin with 
Lipiodol (Lo et  al. 2002). The use of drug-eluting beads 
(DEBs) as doxorubicin-loaded beads rather than doxo-
rubicin Lipiodol emulsion was associated with a better 
toxicity profile, antitumor activity (51.6 vs 43.5 %, respec-
tively), and tolerability (Lammer et al. 2010) with a longer 
time to tumor progression than bland TACE with non-
loaded beads (Malagari et al. 2010).
In neoplastic portal vein thrombosis (PVT), TACE is 
contraindicated, however radioembolization or selective 
internal radiation therapy (SIRT) comprising a catheter-
based delivery of yttrium-90 (90Y)-embedded micro-
spheres into the hepatic artery which selectively emit 
high-energy, low-penetration radiation to the tumor 
(Ibrahim et al. 2008).
A study 2015 compared both SIRTS vs DEBs in the 
management of advanced HCC and revealed that 
although a lower rate of tumor progression was noted in 
the SIRT group, it was nullified by a greater incidence of 
liver cell failure (Pitton et al. 2015).
Sorafenib is an inhibitor of tyrosine protein kinases 
(VEGFR and PDGFR) and Raf kinases (mainly C-Raf than 
B-Raf) (Keating and Santoro 2009), it induces autophagy 
which may interfere with tumor growth. However, drug 
resistance may arise which is of great importance (Zhang 
et al. 2014).
It showed a significant improvement in patients with 
advanced HCC when compared to placebo (hazard 
ratio 0.69; 95 % CI 0.55–0.87; p = 0.0001). Both median 
survival and time to progression showed a 3-month 
improvement. However, there was no difference in the 
quality of life or symptoms caused by progression of liver 
disease due to side effects of the large dose of sorafenib 
(Patt et al. 2004). It is suitable for Child-Pugh class A and 
B with close follow-up.
Capecitabine is a prodrug with complete absorption 
from gastrointestinal mucosa. It is converted to the active 
metabolite 5-fluorouracil by thymidine phosphorylase 
enzyme; the latter exists in higher levels in cancerous tis-
sues and the liver compared with normal tissue render-
ing it more specific and it was found to be safe in patients 
with liver cirrhosis (Twelves et al. 1999).
The increasing number of patients presented with 
advanced HCC with no other eligible treatment options 
that can be offered for them as surgery, local ablative 
therapies or chemoembolization will put us in a chal-
lenging situation, so the aim of this work is to evaluate 
the efficacy of low dose capecitabine combined with 
sorafenib which are potentially safe and effective drugs 
based on previous studies, in subset of Egyptian HCV 
patients presented with advanced HCC who were unfit 
for surgical or loco regional therapies.
Subjects and methods
In the period extending from April 2014 till February 
2016, at Hepatology outpatient clinic—Zagazig Uni-
versity hospital, the efficacy of capecitabine combina-
tion with sorafenib was evaluated in the management of 
advanced inoperable HCC unfit for surgical or locore-
gional therapies, and the patients had an adequate 
hepatic reserve with PS ≤2.
From 60 patients presented with HCC, 15 male 
patients (25  %) were selected according to the prede-
termined inclusion criteria. The number of patients 
was determined according to diagnosed patients dur-
ing this period of the study. They were treated after 
being informed about the possible side effects of medi-
cations and informed consent was obtained from them. 
All procedures performed were in accordance with the 
ethical standards of Zagazig university research commit-
tee and with the 1964 Helsinki declaration and its later 
amendments.
The control group was age and sex matched and divided 
into 2 subgroups; subgroup 1 which included 15 patients 
who received only supportive therapy and subgroup 2 
which included 15 patients who received sorafenib only, 
they were followed up every 2 months.
Inclusion criteria
  • Hepatocellular carcinoma that is not suitable for sur-
gical or loco-regional interventions with adequate 
bone marrow function denoted by average neutrophil 
count more than 1500/µl, Hemoglobin level more 
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than 8.5  g/dl, Platelet count  >60,000/µl. Serum cre-
atinine <2.0 mg/dl, and creatinine clearance >30 ml/
min calculated by Cockcroft–Gault equation. Ade-
quate hepatic reserve (Patients with a Child-Pugh 
class A–B) with Bilirubin <2.8 mg/dl, INR <1.7, albu-
min ≥2.8 gm/dl, ALT and AST ≤three times upper 
limit of normal.
  • Performance Status  <2, i.e. asymptomatic and fully 
active, able to carry on all pre-disease activities or 
symptomatic but completely ambulatory.
Exclusion criteria
  • Any previous systemic therapy including chemother-
apy.
  • Uncontrolled ascites.
  • Unstable cardiac diseases including Congestive heart 
failure > class II NYHA, unstable angina, new onset 
angina, myocardial infarction, or any uncontrolled 
cardiac troubles within the preceding 6  months as 
capecitabine may induce coronary vasospasm.
  • Metastatic disease or any co-morbid state that 
increases the chance of complications of therapy.
  • Thromboembolic events within the past 6  months, 
any hemorrhagic event within 2 months of therapy.
Treatment schedule and follow up
Capecitabine was administered orally once daily at a 
dose of 500 mg per day together with sorafenib 200 mg 
twice daily till return of AFP to normal level then the 
treatment was modified to capecitabine 250  mg every 
other day and sorafenib 400  mg once daily until com-
plete disappearance of the lesions with recanalization of 
the portal vein or non-response in the form of progres-
sion of disease, unbearable toxicity or worsening of liver 
function with progression of Child-Pugh class. The con-
trol group received sorafenib only in a dose of 400  mg 
twice daily or supportive treatment as silymarin 140 mg 
t.d.s, ursodeoxycholic acid 500  mg and symptomatic 
treatment for bleeding tendency and portal hyperten-
sion and abdominal pain.
The safety, tolerability and occurrence of side effects 
with the use of these agents and their effect on tumor size 
were evaluated according to response evaluation criteria 
in solid tumors. evaluation was by computerized tomog-
raphy every 3 months and laboratory follow up including 
liver, kidney function tests, complete blood count and AFP 
every 2 weeks in the first 2 months then every month.
  • Complete response means the disappearance of all tar-
get lesions.
  • Partial response means more than 30  % decrease 
in the sum of the longest diameter of the tumorous 
lesions.
  • Stable disease means neither sufficient decrease nor 
increase in the sum of the longest diameter of the 
lesions to classify them into a progressive or regressive 
category.
  • Progressive disease denotes 20 % increase in the sum 
of the longest diameter of target lesions or the appear-
ance of new lesions (Eisenhauer et al. 2009).
Statistical methods
Data management and statistical analysis were by SPSS 
software version 13. Baseline laboratory markers were 
expressed as mean ± standard deviation (SD) or standard 
of error (SE) when appropriate. Progression-free survival 
and overall survival were analysed by the Kaplan–Meier 
method. Paired t test was used to compare AFP, size and 
number of focal lesions after therapy. ANOVA test was 
used when appropriate, p  <  0.05 indicating statistically 
significance result.
Results
The baseline characteristics of the patients under study 
were shown in Table 1. Four patients had one focal lesion 
(26.7 %), 3 patients had 2 focal lesions (20 %), 5 patients 
had 3 focal lesions (33.3  %), 3 patients had four focal 
lesions (20  %). 11 patients had portal vein thrombo-
sis (73.3 %). The mean of the sum of tumoral size in its 
longitudinal diameter is 10.5 ± 4.1 cm, mean Child Tur-
cotte Pugh score was 6.33 ± 0.3, MELD score 13.7 ± 1.4, 
PS <2.
The patients were given the planned medications and 
followed up after 1  month with AFP level, abdominal 
USG and triphasic CT after 3 months to detect the num-
ber and size of lesions. During therapy, 6 patients devel-
oped rising bilirubin (40  %) to grade 3 which improved 
after adding ursodeoxycholic acid, worsening thrombo-
cytopenia in 4 patients (26.7  %) which improved after 
temporary cessation of therapy with adding vitamin 
B complex and eltrombobag (Revolade) 25  mg daily, 
melena in 2 patients (13.3  %) which were improved 
with temporary cessation of therapy and blood transfu-
sion. Hand and foot syndrome in 3 patients (20 %) which 
was managed by temporary cessation of therapy, topical 
moisturizing and antibiotic creams and paracetamol for 
pain relief.
After 1 month of therapy as shown in Table 2; a highly 
significant reduction in the size of lesions and AFP level 
(p = 0.000) but the number of lesions is not changed.
Three months later, the patients were doing well with 
medications and showed a highly significant reduction of 
the number, size of the lesions with a further significant 
reduction in AFP level.
After further 3  months i.e. after 7  months of therapy; 
a further significant reduction in number and size of 
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lesions (p = 0.001), APF reached a constant level with no 
significant change from the previous reading. 3 patients 
showed complete response with complete disappearance 
of the lesions (20 %).
Three months later (10 months of therapy); non-signifi-
cant reduction in the number and size of lesions, another 
3 patients showed complete response with the disappear-
ance of focal lesions (20  %). AFP mean value unexpect-
edly was higher in one patient (6.7 %) due to recurrence 
of the disease with rising of AFP to 230 ng/ml.
After 10 months of therapy, 6 patients showed a com-
plete response (40  %) and 2 of them showed complete 
recanalization of portal vein so treatment was stopped 
and the others (n =  4) showed partial portal vein reca-
nalization. Patients who achieved complete response 
with partial recanalization of the portal vein or patients 
who achieved partial response i.e. reduction in num-
ber and size of focal lesions (n  =  8, 53.3  %) were kept 
on therapy for 21 days and repeated every 14 days with 
continued follow up every 2 months. One patient (6.7 %) 
showed recurrence of the disease and died after 1 month. 
The medications were safe and tolerable by the patients 
in this low dose regimen.
The control group composed of 30 male patients with 
advanced HCC; they were divided into supportive treat-
ment arm and sorafenib arm, their baseline demographic, 
laboratory and radiological characteristics were shown in 
Table 1. A statistically significant difference in BMI, AST, 
ALT, WBCs, hemoglobin, platelet count and AFP was 
present when compared to the study patients.
The control group showed a highly significant reduc-
tion in survival when compared to the patients who 
received capecitabine and sorafenib (p = 0.000) as shown 
in Table 1 and Fig. 1. It was proved that adding capecit-
abine was more superior to sorafenib alone or treatment 
naïve patients.
Discussion
With the introduction of various radiological and labo-
ratory modalities, still they did not provide sufficient 
sensitivity and specificity for early prediction of HCC 
nor helping patients so much as most of them present at 
the time of diagnosis in an inoperable stage with limited 
chance of curative therapy, so for the majority of patients 
only palliative therapy can be offered.
Administration of systemic chemotherapy to patients 
with advanced liver disease remains a challenging issue. 
Previous studies on capecitabine provided evidence on 
its relative safety and tolerance in patients with average 
functional hepatic reserve (Eklund et al. 2005).
A study conducted at 2004 reported the safe use of 
capecitabine for hepatobiliary cancer, with the occur-
rence of few side effects as palmoplantar erythrodyses-
thesia and mild hematologic toxicity (Patt et al. 2004).
Another study conducted at 2007 which stated that 
capecitabine could be safely given in patients with 
advanced HCC with compensated cirrhosis in an out-
patient setting. One partial response was observed and 
Table 1 Baseline demographic, laboratory and  radiologi-
cal characteristics of the study patients and controls
Italic values indicate significant differences when p < 0.05
SRB sorafenib, CTB capcitabine, BMI body mass index, CTP child turcott pugh, 
MELD model for end stage liver disease, AFP alfafetoprotein
Variable SRB+CTB SRB Supportive p
Age (years) 49.5 ± 5.2 47.2 ± 4.6 46.6 ± 4.3 0.2
BMI k/m2 27.7 ± 0.9 26.8 ± 0.5 27 ± 1.3 0.03
AST IU/l 97.6 ± 26.5 68 ± 15 89.5 ± 28.4 0.005
ALT IU/l 65 ± 12.2 85 ± 17 73.8 ± 11.5 0.001
Albumin gm/dl 3.37 ± 0.32 3.6 ± 0.3 3.4 ± 0.3 0.09
T.Bilirubin mg/dl 2.03 ± 0.3 1.94 ± 0.9 2.2 ± 0.4 0.48
WBC cell/µl 3.7 ± 0.3 4.3 ± 0.4 3.6 ± 0.5 0.000
HB gm/dl 11.2 ± 0.8 11.6 ± 0.6 10.9 ± 0.5 0.02
Platelets cell/µl 91.3 ± 8.3 100 ± 7 94.2 ± 10.2 0.03
INR 1.35 ± 0.08 1.32 ± 0.3 1.4 ± 0.1 0.5
Creatinine mg/dl 1.2 ± 0.5 0.9 ± 0.4 1.1 ± 0.3 0.14
CTP 6.3 ± 0.3 6.7 ± 0.7 6.5 ± 0.2 0.07
MELD 13.7 ± 1.4 14.2 ± 1.6 14 ± 1.2 0.6
AFP ng/dl (mean ± SE) 6211 ± 929 3154 ± 345 2710 ± 581 0.000
No of focal lesions 2.5 ± 1.1 2.4 ± 0.3 2.4 ± 0.9 0.9
Size (cm) 10.5 ± 4.1 11.2 ± 6.3 8.7 ± 2.4 0.3
PVT (n) 11(73.3 %) 12 (75 %) 9 (60 %) 0. 8
Survival (months) 12.9 ± 2.1 7.9 ± 0.9 4.5 ± 1.3 0.000
Table 2 Tracing of the effects of combined therapy on AFP, number and size of focal lesions during the follow up period
1 month 4th month 7th month 10th month Basal
AFP 57 ± 17.5 6.9 ± 1.5 7.1 ± 1.1 21.3 ± 9.4 6211.3 ± 929
p (0.000) (0.000) (0.6) (0.4) –
No of lesions 2.4 ± 1 1.47 ± 0.6 0.93 ± 0.4 0.73 ± 0.34 2.5 ± 1.1
P (p = 0.8) (p = 0.000) (p = 0.001) (p = 0.2) –
Size of lesions 6.4 ± 2.9 3.8 ± 1.8 2.2 ± 1.4 2.2 ± 0.9 10.4 ± 4.1
p (p = 0.000) (p = 0.000) (p = 0.001) (p = 0.8) –
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3-month progression free survival rate was 27  %. The 
median time to tumor progression and median overall 
survival were 2.2 months (95 % CI 1.7–2.7 months) and 
10.1 months (95 % CI 3.0–17.2 months) (Von Delius et al. 
2007).
In patients with  Child-Pugh  Class A, the toxicity 
of these agents occurs with the same frequency as in 
patients with normal hepatic function (Walko and Lind-
ley 2005).
In comparison with doxorubicin; patients treated with 
capecitabine showed 6  months median progression-
free survival, which was much longer than that reported 
about the former (Gish et al. 2007).
The SHARP (Lovet et  al. 2008) and the Asia–Pacific 
(Cheng et  al. 2009) trials revealed that sorafenib was 
associated with a statistically significant improved sur-
vival in advanced HCC with adequate hepatic functional 
reserve however; absolute advantage is unsatisfactory 
(2.8 months among Western patients; 2.3 months among 
Asians).
One of the most important issues is that the favorable 
effects of sorafenib on tumor vascularization and disease 
progression are rapidly lost after stoppage of treatment 
with the possibility of a rebound increase in tumor 
growth (Wolter et  al. 2009), and short courses of treat-
ment could change tumor into a more aggressive pheno-
type (Pàez-Ribes et al. 2009).
The antiangiogenic effect of chemotherapy can be aug-
mented by continuous low-dose administration, and this 
low dose approach is characterized by good tolerability 
and low toxicity profile (Kerbel and Kamen 2004).
A report of 2 cases treated with metronomic capecit-
abine, they showed unexpectedly good therapeutic effi-
cacy and the authors concluded that this treatment might 
be considered in patients unresponsive or intolerant to 
sorafenib, or when sorafenib is contraindicated (Marinelli 
et al. 2013).
Abdel-Rahman et al. (2013) concluded that in advanced 
HCC, capecitabine is inferior to sorafenib in terms of 
median progression-free survival and overall survival, 
and it should not be used alone but combination therapy 
with sorafenib should be considered.
Another case report of good response and long pro-
gression free survival of 50  months when capecitabine 
in low dose was used as a second line therapy in HCC 
resistant or unfit for sorafenib (Solda et al. 2015).
SRB: Sorafenib, CTB: Capcitabine
Fig. 1 Kaplan Meier plot for survival in study and control groups
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Granito et  al. (2015) showed that disease control 
was achieved by metronomic capecitabine in (23  %) of 
patients. Median time-to-progression was 4  months. 
Median overall survival was 8 months (95 % confidence 
interval 3.7–12.3) and they concluded that metronomic 
capecitabine was well tolerated and exhibited a potential 
anti-tumour activity with long-lasting disease control.
In the current study conducted on 15 patients pre-
sented with advanced HCC who were not candidate for 
surgical or loco regional therapy and after their approval 
to be enrolled and treated with the defined therapy; they 
received capecitabine 500  mg per day combined with 
sorafenib 200  mg twice daily till normalization of AFP 
then the treatment was modified to give capecitabine 
250 mg every other day and sorafenib 400 mg once daily 
until complete response, progression of disease, unaccep-
table toxicity.
After 10 months of therapy; 6 patients showed a com-
plete response (40 %). One patient (6.7 %) showed recur-
rence of the disease and died after 1  month, 8 patients 
showed partial response (53.3 %). Patients who were kept 
on medications till now showed accepted safety and tol-
erability with proven highly significant prolongation of 
survival when compared to sorafenib only and treatment 
naïve controls (12.9 ±  2.1, 7.9 ±  0.9, 4.5 ±  1.3  months 
respectively, p = 0.000).
Results are consistent with of Brandi et  al. as regard 
overall survival however the current study showed a 
higher number of patients with complete response; 
their study enrolled 59 patients treated with metro-
nomic capecitabine; median progression-free survival 
of 6.03 months and an overall survival of 14.47 months. 
Two patients achieved a complete response, 1 patient 
achieved partial response (Brandi et al. 2013).
Patients who showed complete response with com-
plete recanalization of the portal vein achieved the end of 
treatment and stopped therapy with continued follow up 
every 2 months.
From data revealed by the current study, combined 
low dose capecitabine and sorafenib proved to be safe, 
enhances the effects of sorafenib, with low toxicity pro-
file and deserves further attention as a convenient, out-
patient-based chemotherapy regimen in patients with 
advanced HCC and adequate hepatic reserve.
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Novelty
Patients with advanced inoperable hepatocellular carcinoma or unfit for loco 
regional therapy, have no way else for a treatment to reduce disease progres-
sion or enhance the duration of their short-term survival, also other modalities 
of chemotherapy inevitably will cause side effects in these patients with 
impaired liver functions. Sorafenib and capecitabine given in small doses with 
close follow-up may provide a safe way to overcome these obstacles.
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